logo
Study Sheds Light On The Origins Of Giant Salt Formations

Study Sheds Light On The Origins Of Giant Salt Formations

Forbes19 hours ago
Outcrops with thick salt deposits in Sicily.
While wandering along the cliffs of the Mediterranean Sea — particularly in southern Italy and Sicily — one might come across outcrops composed entirely of thick layers of salt and gypsum.
Thanks to geophysical surveys and an extensive drilling campaign conducted during the Glomar Challenger expedition, we now know that these salt layers extend beneath the Mediterranean Sea and, in some regions, reach thicknesses of up to 2.5 kilometers. Such deposits can only form by evaporating large amounts of seawater. For almost 200 years scientists wondered how this was possible, and one unique salt lake — the Dead Sea in Israel — may provide an answer.
'These large deposits in the earth's crust can be many, many kilometers horizontally, and they can be more than a kilometer thick in the vertical direction,' says UC Santa Barbara mechanical engineering professor Eckart Meiburg, lead author of a new study. 'How were they generated? The Dead Sea is really the only place in the world where we can study the mechanism of these things today.'
Salinity levels in the Dead Sea are famously so high that only few organisms can survive in its waters, giving it its name.
Indeed, while there are other bodies of water in the world with high salinity levels, only in the Dead Sea they form massive salt deposits, which allows researchers to tackle the physical processes behind their evolution, and in particular, the spatial and temporal variations in their thickness.
In their study, Meiburg and fellow author Nadav Lensky of the Geological Survey of Israel cover the fluid dynamics and associated sediment transport processes currently governing the Dead Sea.
In 2019, the researchers observed a rather unique process occurring in the lake during the summer. While evaporation was increasing the salinity of the water on the surface, salts washed into the lake were nonetheless continuing to dissolve due to its warmer temperature. As the dense, salt-rich water sinks to the ground, it mixes with cooler water rising upwards. At the interface between the two layers, halite (common salt) crystals start to grow. The heavy crystals fall to the bottom, forming a sort of 'salt snow' covering the bottom of the Dead Sea basin.
Detail of the outcrop showing single salt and gypsum crystals.
In addition to other factors including internal currents and surface waves, this process is highly effective in creating salt deposits of various shapes and sizes, the authors conclude.
In contrast to shallower hypersaline bodies in which precipitation and deposition occur during the dry season, in the Dead Sea salt formation occurs during the entire year.
About 5.96 to 5.33 million years ago tectonic forces closed off the Strait of Gibraltar, reducing the inflow from the Atlantic into the Mediterranean basin and creating conditions similar to the Dead Sea basin — but on a vastly larger scale.
'The sea level dropped 3 to 5 kilometers (2-3 miles) due to evaporation, creating the same conditions currently found in the Dead Sea and leaving behind the thickest of this salt crust that can still be found buried below the deep sections of the Mediterranean,' Meiburg explains.
'But then a few million years later the Strait of Gibraltar opened up again, and so you had inflow coming in from the North Atlantic and the Mediterranean filled up again.'
The full study, "Fluid Mechanics of the Dead Sea," was published in the journal Annual Review of Fluid Mechanics and can be found online here.
Additional material and interviews provided by University of California - Santa Barbara.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tirzepatide Tops TRT for Men With Hypogonadism and Obesity
Tirzepatide Tops TRT for Men With Hypogonadism and Obesity

Medscape

time9 hours ago

  • Medscape

Tirzepatide Tops TRT for Men With Hypogonadism and Obesity

San Francisco — Tirzepatide is a promising treatment for metabolic hypogonadism in men with obesity, new research suggested. In a study of 83 men with obesity, functional hypogonadism, and insulin resistance, those treated with the dual glucose-dependent insulinotropic peptide and glucagon-like peptide 1 (GLP-1) receptor agonist tirzepatide for 2 months had greater weight loss, increased endogenous testosterone production, and improved erectile dysfunction compared to those treated with transdermal testosterone replacement therapy (TRT) or who received no treatment. 'Tirzepatide offers a dual benefit, substantial weight loss and restoration of gonadal function in obese men. This may change first-line management strategies for metabolic hypogonadism, encouraging a shift away from immediate testosterone supplementation in select patients,' lead study author Rossella Cannarella, MD, research fellow in the Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, told Medscape Medical News . She added, 'Unlike TRT, which suppresses gonadotropins, tirzepatide appears to restore axis function. This offers an alternative for functional hypogonadism that addresses root metabolic causes rather than symptomatically replacing testosterone.' Cannarella presented the findings at ENDO 2025: The Endocrine Society Annual Meeting. The data were also published recently in Reproductive Biology and Endocrinology . Asked to comment, session co-moderator Olena Klindukhova, MD, assistant professor at the Medical College of Wisconsin, Milwaukee, told Medscape Medical News , 'there are a number of good publications in the past on bariatric surgery patients who were able to achieve improvement in fertility, in testosterone level, and all aspects of sexual function. So, we were waiting the GLP-1 data to come in, and it's great to hear. It will definitely empower my clinical practice. Having patients achieve weight loss will improve their physiologic, natural production of testosterone. This gives us more validation.' Tirzepatide Tops Testosterone in Metabolic, Hormonal Improvements The study participants were allocated to three groups, based on their preferences, health status, and overall circumstances: 28 to tirzepatide (2.5 mg for the first month, increased to 5 mg in the second month), 30 to no pharmacological treatment, and 25 to transdermal testosterone. All were instructed to follow a low-calorie diet and to engage in 20 minutes per day of brisk walking. At baseline, all patients had ED, with International Index of Erectile Function (IIEF-5) scores ranging from 5 to 12. At least half in each group were classified as having severe ED. Baseline waist circumference was significantly higher in the no-treatment group, while baseline scores on the Binge Eating Scale (BES), percentage lean mass, and luteinizing hormone (LH) levels were all significantly higher in the tirzepatide-treated group. After 2 months, the tirzepatide group showed significantly greater improvements from baseline than the other two groups in body weight (-8.1%, vs -2.4% and -3.0% for lifestyle only and testosterone, respectively, P = .0007), BMI, waist circumference, fat mass, and BES score. The tirzepatide group also had a greater increase in lean mass than the lifestyle-alone group but not the testosterone group. All groups showed reductions in insulin resistance, with those in the two pharmacologic treatment groups showing greater reductions than the lifestyle-only group. The increase in IIEF-5 was higher in the tirzepatide group than the lifestyle-only group, and also higher than the testosterone group although not significantly. With tirzepatide, levels of LH, follicle-stimulating hormone (FSH), and total testosterone were significantly higher than in the other two groups, while 17β-estradiol (E 2 ) was lower (all P < .00001). The testosterone-treated group showed smaller changes in most parameters, including a slight increase in E 2 levels. Also asked to comment, session co-moderator Maja Stefanovic-Racic, MD, PhD, associate professor of medicine and director of the endocrinology, diabetes, and metabolism fellowship training program at the University of Pittsburgh School of Medicine, Pennsylvania, told Medscape Medical News , 'I was very impressed is that the GLP-1 improved erectile dysfunction, because we know that especially in obese men, adding testosterone often does not improve ED at all. This may relate to endothelial function outside of weight.' Indeed, Cannarella also pointed out that weight loss might not be the only mechanism contributing to all the observed improvements. 'While weight loss undoubtedly plays a major role, the magnitude and speed of hormonal recovery — along with increases in gonadotropins (LH, FSH) and SHBG [sex hormone-binding globulin] — suggest that tirzepatide may exert additional regulatory effects on the hypothalamic-pituitary-gonadal axis.' Klindukhova commented, 'from an endocrinologist standpoint, if there's a patient who is open to it, I would personally go for GLP-1 over testosterone.' Cannarella, Klindukhova, and Stefanovic-Racic had no disclosures.

Study Sheds Light On The Origins Of Giant Salt Formations
Study Sheds Light On The Origins Of Giant Salt Formations

Forbes

time19 hours ago

  • Forbes

Study Sheds Light On The Origins Of Giant Salt Formations

Outcrops with thick salt deposits in Sicily. While wandering along the cliffs of the Mediterranean Sea — particularly in southern Italy and Sicily — one might come across outcrops composed entirely of thick layers of salt and gypsum. Thanks to geophysical surveys and an extensive drilling campaign conducted during the Glomar Challenger expedition, we now know that these salt layers extend beneath the Mediterranean Sea and, in some regions, reach thicknesses of up to 2.5 kilometers. Such deposits can only form by evaporating large amounts of seawater. For almost 200 years scientists wondered how this was possible, and one unique salt lake — the Dead Sea in Israel — may provide an answer. 'These large deposits in the earth's crust can be many, many kilometers horizontally, and they can be more than a kilometer thick in the vertical direction,' says UC Santa Barbara mechanical engineering professor Eckart Meiburg, lead author of a new study. 'How were they generated? The Dead Sea is really the only place in the world where we can study the mechanism of these things today.' Salinity levels in the Dead Sea are famously so high that only few organisms can survive in its waters, giving it its name. Indeed, while there are other bodies of water in the world with high salinity levels, only in the Dead Sea they form massive salt deposits, which allows researchers to tackle the physical processes behind their evolution, and in particular, the spatial and temporal variations in their thickness. In their study, Meiburg and fellow author Nadav Lensky of the Geological Survey of Israel cover the fluid dynamics and associated sediment transport processes currently governing the Dead Sea. In 2019, the researchers observed a rather unique process occurring in the lake during the summer. While evaporation was increasing the salinity of the water on the surface, salts washed into the lake were nonetheless continuing to dissolve due to its warmer temperature. As the dense, salt-rich water sinks to the ground, it mixes with cooler water rising upwards. At the interface between the two layers, halite (common salt) crystals start to grow. The heavy crystals fall to the bottom, forming a sort of 'salt snow' covering the bottom of the Dead Sea basin. Detail of the outcrop showing single salt and gypsum crystals. In addition to other factors including internal currents and surface waves, this process is highly effective in creating salt deposits of various shapes and sizes, the authors conclude. In contrast to shallower hypersaline bodies in which precipitation and deposition occur during the dry season, in the Dead Sea salt formation occurs during the entire year. About 5.96 to 5.33 million years ago tectonic forces closed off the Strait of Gibraltar, reducing the inflow from the Atlantic into the Mediterranean basin and creating conditions similar to the Dead Sea basin — but on a vastly larger scale. 'The sea level dropped 3 to 5 kilometers (2-3 miles) due to evaporation, creating the same conditions currently found in the Dead Sea and leaving behind the thickest of this salt crust that can still be found buried below the deep sections of the Mediterranean,' Meiburg explains. 'But then a few million years later the Strait of Gibraltar opened up again, and so you had inflow coming in from the North Atlantic and the Mediterranean filled up again.' The full study, "Fluid Mechanics of the Dead Sea," was published in the journal Annual Review of Fluid Mechanics and can be found online here. Additional material and interviews provided by University of California - Santa Barbara.

QoL Deserves More Than a Footnote in Cancer Trials
QoL Deserves More Than a Footnote in Cancer Trials

Medscape

timea day ago

  • Medscape

QoL Deserves More Than a Footnote in Cancer Trials

In a review published in New England Journal of Medicine Evidence , Massimo Di Maio, MD, from the Department of Oncology at the University of Turin in Turin, Italy, and president-elect of the Italian Association of Medical Oncology, offers a detailed analysis of how patient-reported outcomes are used in clinical trials and explains the best practices for interpreting quality-of-life (QoL) data. 'QoL data are increasingly being included in oncology trials,' Di Maio told Univadis Italy, a Medscape Network platform. 'However, the scientific community is less familiar with interpreting — or critically assessing — this type of data compared with more traditional endpoints like progression-free survival or overall survival.' With growing support from scientific societies and regulatory agencies, QoL has become a standard endpoint in many studies. Yet practical guidance on its interpretation remains limited. Di Maio, who also served as lead author of the European Society For Medical Oncology guidelines on the use of patient-reported outcome measures in oncology, views this as a significant gap in the field. 'We must not forget that for many patients — especially those in advanced stages of disease — living well can be just as important, if not more so, than living longer,' he emphasized. He also cautioned that statistical significance does not always translate into meaningful clinical benefit. From Trial Design... To accurately assess QoL and maximize the value of the data, clinical trials must be appropriately designed from the outset. As outlined in the article, phase 3 randomized trials offer the ideal framework for QoL measurement. They allow investigators to compare results between treatment and control groups, tracking changes from baseline and over time. Di Maio explains in the review that randomized trial designs help ensure that any differences observed between study arms are directly linked to the treatment itself. Speaking with Univadis Italy , he also addressed the potential for bias in QoL data collection. 'Some researchers argue that simply knowing they are receiving the experimental treatment may lead patients — perhaps even subconsciously — to perceive a benefit, which could influence patient-reported outcomes like QoL,' he said. Still, Di Maio noted the difficulty in rigorously proving the existence or magnitude of such bias. Ideally, this would be tested by comparing blinded and open-label trials, but these studies are uncommon and logistically challenging. One coordinated analysis, led by Fabio Efficace, PhD, of the Italian Group for Adult Hematologic Diseases, found that trial blinding was not an independent predictor of QoL benefit. While the potential for bias cannot be dismissed, Di Maio believes its real-world impact is likely modest — and that open-label studies can still yield valid and meaningful QoL data. ...To Data Interpretation Few oncology trials designate QoL as a primary endpoint, but this isn't inherently a limitation, Di Maio noted. QoL can still be a valuable secondary endpoint — provided the results are interpreted carefully and in the proper context. One of the central challenges is patient compliance with QoL questionnaires, which tends to be inconsistent. Factors contributing to low completion rates include limited time for clinicians to communicate the importance of QoL data, patient dropout due to disease progression or adverse outcomes, and technical issues such as failures in electronic data capture or patients' unfamiliarity with digital tools. In such cases, Di Maio suggested that having a paper-based backup system can improve data reliability. Ultimately, QoL should not be viewed as an optional or secondary concern, but as a fundamental part of assessing the true value of cancer therapies. Patient-reported outcome measures, while designed to capture quality of life, also offer critical insights into the broader effectiveness and utility of treatments. 'QoL data alone aren't sufficient,' Di Maio emphasized, 'but they are indispensable for understanding the value of a therapy — and for communicating that value clearly to patients.' He concluded that interpreting QoL data accurately is not just a scientific imperative but also an ethical obligation to patients navigating serious and often life-limiting conditions.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store